HUP0301179A3 - Modified factor viii - Google Patents

Modified factor viii

Info

Publication number
HUP0301179A3
HUP0301179A3 HU0301179A HUP0301179A HUP0301179A3 HU P0301179 A3 HUP0301179 A3 HU P0301179A3 HU 0301179 A HU0301179 A HU 0301179A HU P0301179 A HUP0301179 A HU P0301179A HU P0301179 A3 HUP0301179 A3 HU P0301179A3
Authority
HU
Hungary
Prior art keywords
factor viii
modified factor
modified
viii
factor
Prior art date
Application number
HU0301179A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of HUP0301179A2 publication Critical patent/HUP0301179A2/hu
Publication of HUP0301179A3 publication Critical patent/HUP0301179A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU0301179A 2000-09-19 2001-09-19 Modified factor viii HUP0301179A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23404700P 2000-09-19 2000-09-19
US23646000P 2000-09-29 2000-09-29
PCT/US2001/029431 WO2002024723A1 (en) 2000-09-19 2001-09-19 Modified factor viii

Publications (2)

Publication Number Publication Date
HUP0301179A2 HUP0301179A2 (hu) 2003-10-28
HUP0301179A3 true HUP0301179A3 (en) 2006-11-28

Family

ID=26927505

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301179A HUP0301179A3 (en) 2000-09-19 2001-09-19 Modified factor viii

Country Status (12)

Country Link
US (1) US6770744B2 (enExample)
EP (1) EP1319016A4 (enExample)
JP (1) JP2004525608A (enExample)
KR (1) KR100638184B1 (enExample)
CN (1) CN1205221C (enExample)
AU (1) AU2001292861A1 (enExample)
CA (1) CA2422902A1 (enExample)
HU (1) HUP0301179A3 (enExample)
MX (1) MXPA03002256A (enExample)
PL (1) PL206105B1 (enExample)
RU (1) RU2003107100A (enExample)
WO (1) WO2002024723A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
PL1750733T3 (pl) * 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
CA2703948A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
US20110077202A1 (en) * 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
WO2014183056A1 (en) * 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
HRP20210031T1 (hr) 2013-06-24 2021-05-14 Weidong, Xiao Pripravci i metode mutantskog faktora viii
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
CN115094062A (zh) * 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
US20210093735A1 (en) * 2018-04-26 2021-04-01 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
WO2022211791A1 (en) 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof
CN113970279B (zh) * 2021-10-26 2023-07-07 珠海城市职业技术学院 数字式螺旋测微仪
CN114196677A (zh) * 2021-12-30 2022-03-18 广西医科大学第一附属医院 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
CA2225189C (en) * 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier

Also Published As

Publication number Publication date
PL206105B1 (pl) 2010-07-30
EP1319016A4 (en) 2006-05-10
CN1205221C (zh) 2005-06-08
KR20030033074A (ko) 2003-04-26
EP1319016A1 (en) 2003-06-18
WO2002024723A9 (en) 2003-04-03
HUP0301179A2 (hu) 2003-10-28
WO2002024723A1 (en) 2002-03-28
AU2001292861A1 (en) 2002-04-02
JP2004525608A (ja) 2004-08-26
CA2422902A1 (en) 2002-03-28
KR100638184B1 (ko) 2006-10-26
US6770744B2 (en) 2004-08-03
MXPA03002256A (es) 2003-09-10
CN1474830A (zh) 2004-02-11
RU2003107100A (ru) 2004-08-27
PL366199A1 (en) 2005-01-24
US20020182670A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
HUP0300586A3 (en) Modified factor viii
PL366199A1 (en) Modified factor viii
DE60115644D1 (en) Thiazinoxazolidinon
AU3391801A (en) Pyridinylimidazoles
PL359920A1 (en) 4-amino-quinazolines
GB0002847D0 (en) Ampligier arrangement
DE50105205D1 (en) Creatinin-biosensor
AU6803901A (en) Bis-arylsulfones
DE50112740D1 (en) Strangführungselement
AU6619001A (en) Liquid-pourers
AU4686401A (en) Hypotensors
AU4831301A (en) Gm-negative ehv-mutants
GB0009221D0 (en) Risticator
GB0019705D0 (en) Factor
GB0411462D0 (en) Karabiners
GB0002667D0 (en) medicamesnts
GB0416955D0 (en) Factor
AU1852P (en) Tickit xTriticosecale
GB2367734B (en) Cane-cap
AU2117P (en) Gauka Gaura lindheimeri
GB0024300D0 (en) Factor
TW414240U (en) Tent-roof improvement
GB0027368D0 (en) Order form
GB0009389D0 (en) Ward off
AU141656S (en) Eartag

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished